Cargando…
Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease
BACKGROUND: Anti–tumor necrosis factor (TNF) therapy is widely used to treat Crohn’s disease (CD). Unfortunately, 10%–40% of patients have primary non-response to anti-TNF therapy. TNF family genes play crucial roles in inflammation and immune regulation; however, the effects of TNF family genes on...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072632/ https://www.ncbi.nlm.nih.gov/pubmed/35529850 http://dx.doi.org/10.3389/fimmu.2022.871312 |